Dementia biomarkers are crucial indicators used in Alzheimer's disease and other forms of dementia to diagnose, track progression, and assess response to treatment. These biomarkers include proteins like beta-amyloid and tau in cerebrospinal fluid or through imaging techniques like PET scans. Genetic markers such as the APOE ε4 allele also play a significant role. Biomarkers aid in early detection before symptoms manifest, enabling timely interventions. Research focuses on identifying novel biomarkers to enhance diagnostic accuracy and therapeutic targeting, aiming to improve patient outcomes and facilitate the development of disease-modifying treatments. Integrating biomarker findings with clinical assessments enhances diagnostic precision and supports personalized care approaches in managing Alzheimer’s and related dementias.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China